Phase I trial of the combination of ibrutinib and lenalidomide of the treatment of patients with MDS who have failed standard therapy or who are unfit for or refuse standard therapy
- Resource Type
- Correspondence
- Source
- In
Leukemia Research November 2022 122 - Subject
- Language
- ISSN
- 0145-2126